Sou Hu Cai Jing·2026-02-27 01:37Group 1 - The restructuring of the international monetary order will remain a key theme for global assets in 2026, with trends supporting a bull market for Chinese stocks and gold, and favoring Chinese stocks over US stocks [1] Group 2 - In the domestic blood products industry, the proportion of domestic albumin batch approvals is increasing, with stable performance in albumin, immunoglobulin, and fibrinogen approvals expected in 2025 [2] - The growth rate of approvals for VIII factor and PCC is rapid, while the approvals for certain products like immunoglobulin are also showing good growth [2] - Companies are focusing on the development of recombinant products and new immunoglobulins, with ongoing research and development efforts [2] - The blood products industry in 2026 should focus on plasma station expansion, industry mergers and acquisitions, and progress in new product development [2] Group 3 - The insurance sector is expected to continue benefiting from strict regulations and a competitive environment over the next 3-5 years, leading to increased market share concentration among major players [3] - The low interest rate environment is driving savings deposits towards insurance companies, creating a win-win situation for banks, insurance companies, and customers, which is likely to persist long-term [3] - There is high certainty for growth in policy sales, investment income, and profits in 2026, especially given the low base in 2025, with recent adjustments in AI narratives providing investment opportunities [3]